Hematopoietic Cell Transplantation in Myelodysplastic Syndromes

Antonio Di Stasi, Armin Ghobadi, Partow Kebriaei

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


This chapter provides case studies of patients with myelodysplastic syndromes (MDS) and their treatment, including hematopoietic stem cell transplantation (HSCT). Regarding the optimal intensity of the induction regimen, published data seem to favor a transplant performed with minimal burden of disease, especially in reduced-intensity conditioning (RIC) regimens that most heavily rely on the graft-versus-leukemia (GVL) effect. Lenalidomide has proved effective in MDS with del(5q); about two-thirds of patients become transfusion independent, with a median response duration of 2.2 years; it has also been shown to be effective in non-del(5q) MDS. In patients with progressive disease, as evidenced by cytogenetic progression and worsened cytopenias, it is reasonable to consider HSCT. If a matched related or matched unrelated donor is unavailable, transplant from a UCB or haploidentical donor is reasonable in very high-risk cases. Secondary MDS is an absolute indication for allogeneic HSCT, in light of the poor prognosis of this disease.

Original languageEnglish
Title of host publicationCancer Consult
Subtitle of host publicationExpertise for Clinical Practice
PublisherWiley Blackwell
Number of pages5
ISBN (Electronic)9781118589199
ISBN (Print)9781118589212
StatePublished - Jun 20 2014


  • Graft-versus-leukemia (GVL) effect
  • Hematopoietic stem cell transplantation (HSCT)
  • Lenalidomide
  • Myelodysplastic syndromes (MDS)
  • Reduced-intensity conditioning (RIC)


Dive into the research topics of 'Hematopoietic Cell Transplantation in Myelodysplastic Syndromes'. Together they form a unique fingerprint.

Cite this